Company / Cash per Share
Vertex Pharmaceuticals Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$19.79
FY2025
5-year range
$17.73 / $41.28
FY2021-FY2025
Trend
+11.6%
vs FY2024
Sector context
#9 of 205
Health Care
What the data says
Among 205 Health Care companies, Vertex Pharmaceuticals is in the top 4% for cash per share. Cash per Share returned to growth in FY2025 after 2 years of decline, reaching $19.79.
Based on SEC 10-K filings.
19.79 in FY2025 with a 5-year CAGR of -3.1%. Top quartile in the Health Care sector.
Declined from $40.34 to $19.79 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -21.7%
- 5-Year CAGR
- -3.1%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 205This company $19.79 Sector average $72.93
▼
-72.9% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 11.6% year-over-year.
- Ranks #9 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2022.
- Lowest cash per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.79 | +11.6% |
| FY2024 | $17.73 | -56.0% |
| FY2023 | $40.34 | -2.3% |
| FY2022 | $41.28 | +57.9% |
| FY2021 | $26.15 | +13.1% |
| FY2020 | $23.12 | +89.7% |
| FY2019 | $12.19 | +16.4% |
| FY2018 | $10.46 | +56.0% |
| FY2017 | $6.71 | +39.5% |
| FY2016 | $4.81 | +62.6% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026